A microfluidics platform for engineering activated antigen carrier immunotherapies from red blood cells showed promising preliminary results in a mouse model.
This single-arm, phase 2 study of pembrolizumab in advanced solid tumor cancers did not limit patient enrollment based on tumor PD-L1 expression level.
Greater increase seen for distant-stage and regional-stage SCCA than for localized-stage SSCA.
Authors call for new screening strategies for anal cancer prevention in women living with HIV.
High tumor expression of IDO1 may identify whether a patient is likely to respond to immunotherapy, according to study authors.
Healthy HIV-positive patients with anal cancer are treated with standard chemoradiotherapy, but whether this patient population experiences worse outcomes or more severe toxic effects was previously unknown.
Researchers are evaluating whether DPX-E7 vaccination is safe and will improve outcomes among patients with HPV-positive head and neck, cervical, or anal cancer.
Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
Addition of cetuximab to definitive chemoradiation (CRT) reduces locoregional failure rates but is associated with grade 4 toxicity.
Care at radiation oncology centers with a higher volume is associated with improved survival among patients with squamous cell carcinoma of the anal canal.
